Topiramate augmentation in clozapine-treated patients with schizophrenia: Clinical and metabolic effects

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 706-710

  Hahn, Margaret K ^a,b   Remington, Gary ^a,b,c   Bois, Daniel ^a   Cohn, Tony ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

clozapine; psychopathology; topiramate; treatment refractory schizophrenia; weight gain

Indexed keywords

CLOZAPINE; TOPIRAMATE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BLOOD CELL COUNT; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; METABOLIC DISORDER; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 78649362141     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181fab67d     Document Type: Article

References (37)

1. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull. 1995;21(4):579-591.
2. Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843-872.
3. Topiramate (Topomax). Physcian's Desk Reference. Montvale. NJ: Medical Economics Co, Inc, 2005:2541-2549.
4. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2009;23:157-162.
5. Deutsch SI, Schwartz BL, Rosse RB, et al. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol. 2003;26: 199-206.
6. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005;66: 1012-1015.
7. Deutsch SI, Rosse RB, Schwartz BL, et al. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol. 2001;24:43-49.
8. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
9. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
10. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
11. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-363.
12. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res. 2006;82:115-117.
13. Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28:169-175.
14. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000;45:198.
15. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 2002;63:1045.
16. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci. 2005;59(5):613-615.
17. Levy E, Agbokou C, Ferreri F, et al. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol. 2007;14:e234Ye239.
18. Narula PK, Rehan HS, Unni KE, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010;118:218-223.
19. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812.
20. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993:39-44.
21. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
22. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Ed. Rockville, MD: US Department of Health; 1976.
25. Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42:387-392.
26. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
27. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol. 2001;15:297-301.
28. Millson RC, Owen JA, Lorberg GW, et al. Topiramate for refractory schizophrenia. Am J Psychiatry. 2002;159:675.
29. Navarro V, Pons A, Romero A, et al. Topiramate for clozapine-induced seizures. Am J Psychiatry. 2001;158:968-969.
30. Migliardi G, D'Arrigo C, Santoro V, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol. 2007;30:107-113.
31. Bourgeois BF. Pharmacokinetics and metabolism of topiramate. Drugs Today (Barc). 1999;35(1):43-48.
32. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol. 1996;16(2):177-187.
33. Stenlof K, Rossner S, Vercruysse F, et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007;9:360-368.
34. Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30: 1480-1486.
35. Eliasson B, Gudbjornsdottir S, Cederholm J, et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond). 2007;31:1140-1147.
36. Besag FM. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf. 2004;3:1-8.
37. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44(3):339-347.